Faeth Therapeutics Establishes $150 Million At-The-Market Equity Offering Program

On June 18, 2026, Faeth Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC to establish an 'at-the-market' (ATM) equity offering program. Under the terms of the agreement, the company may offer and sell shares of its common stock having an aggregate offering price of up to $150,000,000. TD Securities will act as the sales agent and will be entitled to a commission of up to 3.0% of the aggregate gross sales price of any shares sold. Faeth Therapeutics is under no obligation to sell any shares and may suspend or terminate the agreement at any time. Additionally, the company reported that on June 15, 2026, approximately 24,436 shares of Series B Non-Voting Convertible Preferred Stock automatically converted into 24,435,594 shares of common stock. Following this conversion, the company has 25,778,754 shares of common stock outstanding. The ATM shares will be issued pursuant to a Registration Statement on Form S-3 filed on the same day as the agreement.